Drugs / Contezolid
Contezolid
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06811025 | Feb 2024 → Dec 2025 overdue | meningitis, tuberculosis | Beijing Chest Hospital | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06811012 | Jan 2024 → Dec 2025 overdue | disease of bone structure, tuberculosis | Beijing Chest Hospital | Enrolling by invitation | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07372781 | Jan → Dec 2026 expected | mycobacterial infectious disease | Beijing Chest Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT02269319 | Feb → Aug 2015 | bacterial infectious disease | MicuRx | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06081361 | Dec 2023 → Oct 2026 expected | pulmonary tuberculosis, rifampicin-resistant tuberculosis | Beijing Chest Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05369052 | May 2022 → Jun 2026 overdue | — | MicuRx | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07084402 | Jul 2025 → Jul 2027 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT07213765 | Jul 2025 → Sep 2028 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-12-16 | MicuRx | Results “世界肺部健康大会”传佳音 含康替唑胺的创新抗结核方案绽光彩 micurx.com ↗
INSPIRE-CODA研究团队纳入的212例患者的临床数据显示，含康替唑胺的创新短程方案不仅早期疗效非劣于传统长程方案，更在安全性上实现突破——神经系统与血液系统不良反应发生率较传统方案显著降低。 |
| 2025-10-21 | MicuRx | Results IDWeek 2025 亮点 | 中国创新抗菌药康替唑胺 / MRX-5 携 7 项研究/报告登场，直击细菌感染治疗难题 micurx.com ↗
研究中康替唑胺表现出中等的脑脊液穿透率（9.04%–14.08%），有望成为成人中枢神经系统结核病的一种治疗选择。 |
| 2023-09-21 | MicuRx | Regulatory 盟科药业：康替唑胺片和MRX-4获得美国FDA的合格传染病产品和快速通道资格认定 micurx.com ↗
近日，盟科药业宣布美国FDA授予康替唑胺片和MRX-4（contezolid acefosamil）用于治疗中度至重度糖尿病足感染且不伴有骨髓炎适应症合格传染病产品（QIDP）和快速通道（Fast Track）资格认定。 |
| 2019-09-19 | MicuRx | Results 盟科医药宣布新型抗菌药康泰唑胺（Contezolid）针对复杂性皮肤及软组织感染的中国三期临床试验获得积极结果 micurx.com ↗
上海，中国和福斯特城，加州，美国 – 2019 年 9 月 19 日，盟科医药今天宣布，其首个抗菌新药康泰唑胺（contezolid，又名 MRX-I)，在中国开展的一项治疗复杂性皮肤及软组织感染（cSSTI）的关键性三期临床试验获得积极结果。 |
| 2018-09-21 | MicuRx | Regulatory 盟科医药宣布Contezolid和Contezolid acefosamil获得美国FDA的QIDP和Fast Track认定 micurx.com ↗
加州福斯特城和中国上海 -2018年9月21日，盟科医药今天宣布美国食品药品监督管理局（FDA）授予contezolid（MRX-I）和其前药contezolid acefosamil (MRX-4)用于治疗急性细菌皮肤和皮肤组织感染（ABBSSI）的合格感染疾病产品（QIDP）和快速审评（fast track）认定。 |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-16 | MicuRx | “世界肺部健康大会”传佳音 含康替唑胺的创新抗结核方案绽光彩 micurx.com ↗ |
| 2025-10-21 | MicuRx | IDWeek 2025 亮点 | 中国创新抗菌药康替唑胺 / MRX-5 携 7 项研究/报告登场，直击细菌感染治疗难题 micurx.com ↗ |
| 2023-09-21 | MicuRx | 盟科药业：康替唑胺片和MRX-4获得美国FDA的合格传染病产品和快速通道资格认定 micurx.com ↗ |
| 2019-09-19 | MicuRx | 盟科医药宣布新型抗菌药康泰唑胺（Contezolid）针对复杂性皮肤及软组织感染的中国三期临床试验获得积极结果 micurx.com ↗ |
| 2019-09-09 | MicuRx | 盟科医药宣布新型抗生素康泰唑胺磷酸盐（ Contezolid Acefosamil）在美国开展的针对 ABSSSI的二期临床试验获得积极结果 micurx.com ↗ |
| 2018-09-21 | MicuRx | 盟科医药宣布Contezolid和Contezolid acefosamil获得美国FDA的QIDP和Fast Track认定 micurx.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Contezolid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06811025 ↗ |
| Known as | MRX-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3287379 ↗ |
| Known as | MRX-I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02269319 ↗ |
| Action | Inhibit | “It inhibits bacterial growth by interfering with protein synthesis through its translational inhibitory effect on bacteria.” NCT06811025 ↗ |
| Modality | Small molecule | “novel oxazolidinone antibiotic” NCT06811025 ↗ |
| Route | Oral | “Oral MRX-I 800mg given twice a day for 10 days” NCT02269319 ↗ |